Oncology Today—May 18, 2026

This week’s Oncology update highlights regulatory approvals, breakthrough designations, Phase 3 progress, and expanding activity across breast, bladder, prostate, and rare cancers.

In Today’s Newsletter

Dive deeper

Ask Google AI

Ask ChatGPT

Ask Perplexity

Ask Grok

💊 Enhertu expands into early HER2-positive breast cancer [1] [US • 15 May 2026]

https://www.astrazeneca.com/media-centre/press-releases/2026/enhertu-approved-in-two-her2-early-bc-settings.html
Context: FDA approved Enhertu for neoadjuvant Stage II or III HER2-positive breast cancer and adjuvant use after residual invasive disease.
Key point: Enhertu (trastuzumab deruxtecan, AstraZeneca and Daiichi Sankyo) was reviewed using DESTINY-Breast11 and DESTINY-Breast05 Phase 3 data.
Implication: May influence prescriber choice and payer reviews pending full data.

🧬 PADCEV plus Keytruda filed in Japan for cisplatin-eligible MIBC [2] [Japan • 14 May 2026]

https://newsroom.astellas.com/2026-05-14-astellas-submits-supplemental-new-drug-application-in-japan-for-padcev-plus-keytruda-in-cisplatin-eligible-patients-with-mibc
Context: PADCEV (enfortumab vedotin) plus Keytruda (pembrolizumab) reduced risk of recurrence, progression, or death by 47%, and death risk by 35%.
Key point: Astellas based the sNDA on EV-304, also known as KEYNOTE-B15, in cisplatin-eligible muscle-invasive bladder cancer.
Implication: May influence prescriber choice and payer reviews pending full data.

🧫 Emi-Le gets FDA Breakthrough Therapy Designation in ACC [3] [US • 12 May 2026]

https://servier.mediaroom.com/2026-05-12-Emiltatug-Ledadotin-Emi-Le-Granted-Breakthrough-Therapy-Designation-by-the-U-S-FDA-for-Adenoid-Cystic-Carcinoma-ACC
Context: FDA granted Breakthrough Therapy Designation for locally advanced, recurrent, or metastatic ACC with solid histology or high-grade transformation.
Key point: Emi-Le (emiltatug ledadotin, Servier) is an investigational B7-H4-directed ADC in Phase 1 testing.
Implication: May influence prescriber choice and payer reviews pending full data.

☢️ Pluvicto deepens PSA responses in mHSPC [4] [17 May 2026]

https://www.novartis.com/news/media-releases/new-psmaddition-data-show-58-lower-risk-psa-progression-pluvicto-metastatic-hormone-sensitive-prostate-cancer
Context: Pluvicto plus standard of care lowered PSA progression risk by 58% versus standard of care alone.
Key point: Novartis reported PSMAddition data for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) plus ARPI and ADT in PSMA-positive mHSPC.
Implication: May influence prescriber choice and payer reviews pending full data.

🧪 IBI363 receives China BTD in MSS/pMMR metastatic CRC [5] [China • 11 May 2026]

https://en.innoventbio.com/InvestorsAndMedia/PressReleaseDetail?key=590
Context: China’s NMPA CDE granted Breakthrough Therapy Designation in advanced MSS/pMMR metastatic CRC after at least two prior lines.
Key point: IBI363 (Innovent, Takeda; PD-1/IL-2α-bias bispecific fusion protein) is being tested with bevacizumab.
Implication: Signals pipeline investment and modality expansion.

🎯 BIZENGRI approved for NRG1-positive cholangiocarcinoma [6] [US • 11 May 2026]

https://www.partnertx.com/partner-therapeutics-announces-fda-approval-of-bizengri-zenocutuzumab-zbco-for-nrg1-fusion-positive-cholangiocarcinoma/
Context: BIZENGRI (zenocutuzumab-zbco, Partner Therapeutics) was approved for advanced unresectable or metastatic NRG1-positive cholangiocarcinoma after prior therapy.
Key point: FDA reviewed eNRGy, a multicenter, open-label Phase 2 trial in NRG1 fusion-positive solid tumors.
Implication: Introduces competition that may affect pricing and formulary access.

🧴 NUBEQA plus ADT supports mCSPC efficacy in ARASEC [7] [US • 15 May 2026]

https://www.bayer.com/en/us/news-stories/arasec-data Context: NUBEQA plus ADT reduced risk of progression or death by 71%, with study limits including no randomization and external control use.
Key point: ARASEC is a US, open-label Phase 2 study comparing NUBEQA (darolutamide) plus ADT with a matched historical ADT-alone control.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🚰 UGN-103 shows six-month response durability in UTOPIA [8] [US • 15 May 2026]

https://investors.urogen.com/news-releases/news-release-details/urogen-reports-945-six-month-duration-response-phase-3-utopia
Context: UGN-103 achieved 94.5% six-month duration of response by Kaplan-Meier estimate; UroGen plans an NDA in Q3 2026.
Key point: UTOPIA is a single-arm Phase 3 trial of UGN-103 (UroGen; mitomycin intravesical solution) in recurrent LG-IR-NMIBC.
Implication: May influence prescriber choice and payer reviews pending full data.

🧬 CAN-2409 shows extended prostate cancer benefit [9] [US • 15 May 2026]

https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-reports-extended-clinical-benefit-over
Context: Aglatimagene besadenovec (CAN-2409) improved prostate cancer-specific disease-free survival by 39% versus placebo.
Key point: Candel reported extended follow-up from a randomized, double-blind Phase 3 trial in intermediate- to high-risk localized prostate cancer.
Implication: May influence prescriber choice and payer reviews pending full data.

🗣️ J&J survey highlights NMIBC treatment burden [10] [Global • 14 May 2026]

https://www.jnj.com/media-center/press-releases/groundbreaking-global-survey-captures-the-significant-patient-burden-experienced-with-current-standard-of-care-bladder-cancer-treatments-underscoring-urgency-for-continued-innovation
Context: More than 90% of patients who underwent bladder removal or BCG reported negative impacts across most life aspects.
Key point: The Harris Poll surveyed 817 NMIBC patients and 802 urologists across the US, Mexico, Brazil, Japan, Germany, and France.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

Why it matters

• Curative-intent oncology is a major theme, with Enhertu, PADCEV plus Keytruda, and CAN-2409 focused on earlier disease settings.
• ADC momentum continues across breast cancer, bladder cancer, and rare tumors, including Enhertu, PADCEV, Emi-Le, and BIZENGRI.
• Urology oncology was prominent, with updates from Novartis, Bayer, UroGen, Candel, and Johnson & Johnson.
• Regulatory acceleration remains active, including FDA approvals, FDA Breakthrough Therapy Designation, and China NMPA Breakthrough Therapy Designation.
• Patient-experience data are becoming more visible in oncology narratives, especially in NMIBC treatment burden and care disruption.

📚 Discover the full Oncology archive on our research hub page.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.